Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/leader-2021-000532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.
N Engl J Med
May 2025
NIHR Oxford Respiratory Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Background: Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive pulmonary disease (COPD).
Methods: In a phase 3, double-blind, randomized, placebo-controlled trial, patients with COPD, a history of exacerbations, and a blood eosinophil count of at least 300 cells per microliter who were receiving triple inhaled therapy were assigned, in a 1:1 ratio, to receive mepolizumab (at a dose of 100 mg) or placebo subcutaneously every 4 weeks for 52 to 104 weeks. The primary end point was the annualized rate of moderate or severe exacerbations.
Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single-Dose Study.
Clin Pharmacol Drug Dev
March 2025
Clinical Research Unit, PPD, Austin, TX, USA.
Article Synopsis
- The study compared the bioavailability of the anti-interleukin-5 antibody depemokimab when delivered using a safety syringe device (SSD) versus an autoinjector (AI) in healthy adults.
- Both methods showed similar plasma concentration profiles and pharmacokinetic parameters, confirming that they are bioequivalent.
- Adverse events were minor and comparable between the two delivery methods, with headaches being the most common side effect, indicating both devices are safe for administering depemokimab.
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
Ann Am Thorac Soc
January 2023
Department of Biostatistics, Epidemiology, and Informatics and.
Sex-based differences in pulmonary arterial hypertension (PAH) are known, but the contribution to disease measures is understudied. We examined whether sex was associated with baseline 6-minute-walk distance (6MWD), hemodynamics, and functional class. We conducted a secondary analysis of participant-level data from randomized clinical trials of investigational PAH therapies conducted between 1998 and 2014 and provided by the U.
View Article and Find Full Text PDFTerminal Digit Preference in Pulmonary Hypertension Endpoints.
Am J Respir Crit Care Med
June 2022
University of Pennsylvania Philadelphia, Pennsylvania.
BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
Chest
August 2022
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address:
Background: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox" in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies.
Research Question: Does BMI modify treatment effectiveness in PAH?
Study Design And Methods: Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.